News on lab-developed tests and emerging diagnostic technologies.
Following variable Phase III outcomes, investigators are searching for more informative biomarkers than PD-L1 expression in advanced urothelial carcinoma cases.
The deal, which was approved by the boards of directors of both companies, is expected to close in the second half of 2021, pending customary conditions.
Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.
The test detects the presence of two biomarkers within a single cell associated with HPV infections that can progress to cervical cancer.
The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.
